More Concerns About Xarelto Bleeding After Two New Studies

By | September 1, 2015

Two new studies have raised additional issues and concerns about Xarelto (rivaroxaban) safety after excessive bleeding on several occasions has happened after patients used the medication. The anticoagulant drug is linked to serious side effects that could lead to hospitalization and even death.

The FDA in 2011 accepted Xarelto to decrease the chance of blood clots following hip and knee replacement surgery.

Within only a year of being on the marketplace,  the drug was praised as a go to for every one but in the harsh reality it was linked to adverse side effects  blood clots, pulmonary embolisms, and much more, with hundreds of adverse events happening yearly.

Particularly, Even bleeding of the eye occurred between the retina and the lens of the eye. All three patients who experience bleeding of the eye were also taking  Xarelto.

The physicians noted the drug is “increasingly prescribed as a replacement for warfarin sodium in the managing of atrial fibrillation,” but that it has a high probable chance it could be related to eye bleeding. They included that the danger could be elevated when patients are switched from a different blood thinner to Xarelto quickly.


Researchers Analyze Xarelto Gastrointestinal Bleeding

Participants were 18 years or older, and had filled a prescription for one of the three drugs during the analysis interval. The last sample of just over 46,000 patients comprised 4,907 using 1,649 using Xarelto Pradaxa, and 39,607 using

Other Studies Advocate Blood Tracking for Aged and Japanese Patients

Other research have raised issues about Xarelto in particular people, including the Japanese and senior patients. As an example, in 2014, 29%  more seniors where risk for bleeding after warfarin. A second 2015 study demonstrated a higher risk in those taking xarelto.

Researchers reasoned that these vulnerable groups would reap the benefits of routine blood monitoring while taking Xarelto. The producers, however, have encouraged Xarelto as a more “suitable” alternative to warfarin, in that it does not need routine blood monitoring.

Now, about 500 Xarelto suits are pending in state and national litigation that is consolidated.